摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

gallium;trinitrate | 13494-90-1

中文名称
——
中文别名
——
英文名称
gallium;trinitrate
英文别名
(2-Oxo-1,3,2,4-dioxazagalletidin-2-ium-4-yl) nitrate;nitrate
gallium;trinitrate化学式
CAS
13494-90-1
化学式
GaN3O9
mdl
——
分子量
255.74
InChiKey
CHPZKNULDCNCBW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    110°C (dec.)
  • 溶解度:
    溶于水、乙醇、乙醚
  • 暴露限值:
    ACGIH: TWA 2 ppm; STEL 4 ppmOSHA: TWA 2 ppm(5 mg/m3)NIOSH: IDLH 25 ppm; TWA 2 ppm(5 mg/m3); STEL 4 ppm(10 mg/m3)
  • 物理描述:
    Gallium nitrate appears as white crystals. (NTP, 1992)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.1
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    189
  • 氢给体数:
    0
  • 氢受体数:
    9

ADMET

毒理性
  • 药物性肝损伤
化合物:硝酸镓
Compound:gallium nitrate
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
DILI 注解:模糊的 DILI 关注
DILI Annotation:Ambiguous DILI-concern
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
严重程度等级:3
Severity Grade:3
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
“标签部分:不良反应”
Label Section:Adverse reactions
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
毒理性
  • 药物性肝损伤
参考文献:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-批准的药物标签用于研究药物诱导的肝损伤,《药物发现今天》,16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: 按照在人类中发展药物诱导肝损伤风险排名的最大参考药物列表。《药物发现今天》2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007 M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
来源:Drug Induced Liver Injury Rank (DILIrank) Dataset
吸收、分配和排泄
  • 消除途径
硝酸镓既不被肝脏也不被肾脏代谢,似乎主要通过肾脏排出。
Gallium nitrate is not metabolized either by the liver or the kidney and appears to be significantly excreted via the kidney.
来源:DrugBank
吸收、分配和排泄
  • 清除
0.15升/小时/千克 [接受每日输注硝酸镓200毫克/平方米,连续5或7天的癌症患者]
0.15 L/hr/kg [cancer patients receiving daily infusion of gallium nitrate at a dose of 200 mg/m2 for 5 or 7 days]
来源:DrugBank

安全信息

  • TSCA:
    Yes
  • 危险等级:
    5.1
  • 安全说明:
    S17,S26,S36/37/39
  • 危险类别码:
    R8,R36/37/38
  • WGK Germany:
    3

SDS

SDS:037292594b6943fd509f3b603fb2649e
查看
Name: Gallium(iii) nitrate hydrate 99.9998% Material Safety Data Sheet
Synonym: Gallium nitrate; Gallium trinitrate; Nitric acid, gallium (3+) sal
CAS: 13494-90-1
Section 1 - Chemical Product MSDS Name:Gallium(iii) nitrate hydrate 99.9998% Material Safety Data Sheet
Synonym:Gallium nitrate; Gallium trinitrate; Nitric acid, gallium (3+) sal

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
13494-90-1 Gallium(III) nitrate hydrate 99.9998 236-815-5
Hazard Symbols: XI O
Risk Phrases: 36/38 8

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes and skin. Contact with combustible material may cause fire.Hygroscopic (absorbs moisture from the air).
Potential Health Effects
Eye:
Causes eye irritation. May cause conjunctivitis.
Skin:
Causes severe skin irritation.
Ingestion:
May cause burns to the gastrointestinal tract. May cause nausea, vomiting, and diarrhea, possibly with blood.
Inhalation:
Causes respiratory tract irritation. May cause acute pulmonary edema, asphyxia, chemical pneumonitis, and upper airway obstruction caused by edema.
Chronic:
Effects may be delayed.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid immediately. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. Do not use mouth-to-mouth resuscitation if victim ingested or inhaled the substance; induce artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper respiratory medical device.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. Strong oxidizer. Contact with other material may cause fire. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use water with caution and in flooding amounts. Runoff to sewer may create fire or explosion hazard.
Extinguishing Media:
Use water only! Contact professional fire-fighters immediately. Do NOT use dry chemicals, CO2, Halon or foams.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Cover with sand, dry lime or soda ash and place in a closed container for disposal. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Keep container tightly closed. Avoid contact with clothing and other combustible materials.
Do not get on skin or in eyes. Avoid ingestion and inhalation. Use only in a chemical fume hood. Wash clothing before reuse.
Storage:
Keep away from heat, sparks, and flame. Do not store near combustible materials. Store in a tightly closed container. Store under nitrogen. Store in a cool, dry area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 13494-90-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves and clothing to prevent skin exposure.
Clothing:
Wear appropriate clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 110 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: > 110 deg C
Solubility in water: Soluble.
Specific Gravity/Density: Not available.
Molecular Formula: GaN3O9.xH2O
Molecular Weight: 255.74

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures. Moisture sensitive.
Conditions to Avoid:
Incompatible materials, ignition sources, dust generation, excess heat, combustible materials, reducing agents.
Incompatibilities with Other Materials:
Strong reducing agents, strong acids, acids, isocyanates, cyanides (e.g. potassium cyanide, sodium cyanide), hypophosphites, moisture, thiocyanates, aluminum powder + water, alkyl esters, phosphinates + heat, heavy metals.
Hazardous Decomposition Products:
Nitrogen oxides.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 13494-90-1: LW9625000 LD50/LC50:
CAS# 13494-90-1: Oral, mouse: LD50 = 4360 mg/kg; Oral, mouse: LD50 = 4400 mg/kg.
Carcinogenicity:
Gallium(III) nitrate hydrate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRATES, INORGANIC, N.O.S.
Hazard Class: 5.1
UN Number: 1477
Packing Group: II
IMO
Shipping Name: NITRATES, INORGANIC, N.O.S.
Hazard Class: 5.1
UN Number: 1477
Packing Group: II
RID/ADR
Shipping Name: NITRATES, INORGANIC, N.O.S.
Hazard Class: 5.1
UN Number: 1477
Packing group: II

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI O
Risk Phrases:
R 36/38 Irritating to eyes and skin.
R 8 Contact with combustible material may cause
fire.
Safety Phrases:
S 17 Keep away from combustible material.
WGK (Water Danger/Protection)
CAS# 13494-90-1: No information available.
Canada
CAS# 13494-90-1 is listed on Canada's NDSL List.
CAS# 13494-90-1 is listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 13494-90-1 is listed on the TSCA inventory.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生产方法

三氧化二镓溶于硝酸。蒸发溶液,浓缩后加。反复进行这一操作,直至浓溶液中无硝酸臭味。然后加稀释,使每100 mL溶液中含26 g。将黏稠溶液冷却可析出Ga(NO3)3·xH2O。抽滤,所得结晶于室温下真空干燥,然后在40℃条件下干燥48小时,即得到无物。

类别

氧化剂

毒性分级

中毒

急性毒性

口服 - 小鼠 LD50: 4360 毫克/公斤

刺激数据

皮肤 - 哺乳动物 500 毫克 重度

爆炸物危险特性

与还原剂、等混合受热、撞击或摩擦时可能发生爆炸。

可燃性危险特性

与有机物、还原剂、易燃物如混合可燃;受热分解生成有毒的氧化氮气体。

储运特性

应存放在通风、低温干燥的地方,轻装轻卸。与有机物、还原剂、等易燃物分开存放。

灭火剂

使用雾状或砂土进行灭火。

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    EMELYANOVA, O. N.;BELOUS, A. I.;MELNIKOV, V. D.;GRIGOREVA, I. K.;KUDRYAVT+, AKTUAL. VOPR. TEXNOL. NEORGAN. REAKTIVOV I OSOBO CHIST. VESHCHESTV, M.,(1+
    摘要:
    DOI:
  • 作为产物:
    描述:
    Gallium trinitrate hydrate 以 为溶剂, 生成 gallium;trinitrate
    参考文献:
    名称:
    CATALYST COMPOSITION FOR SELECTIVE CATALYTIC REDUCTION OF EXHAUST GASES
    摘要:
    一种催化剂组合物,包括由公式XVO4/S表示的钒酸盐,其中XVO4表示Bi-、Sb-、Ga-和/或Al-钒酸盐,可选地与一种或多种稀土金属钒酸盐混合,或与一种或多种过渡金属钒酸盐混合,或与一种或多种过渡金属钒酸盐和一种或多种稀土金属钒酸盐混合,S是一种支撑材料,包括TiO2,可选地与掺杂剂组合,以及制备这种催化剂组合物的方法。
    公开号:
    US20130040808A1
点击查看最新优质反应信息

文献信息

  • Preparation of high emission efficiency alkaline earth metal thiogallate phosphors
    申请人:——
    公开号:US20020014614A1
    公开(公告)日:2002-02-07
    A method of forming high efficiency emission alkali metal activated gallium sulfide phosphors by including an excess of 1-7% of gallium. A solution of a soluble gallium salt is added to a sulfate precipitate of an alkali metal sulfate and firing in hydrogen sulfide atmosphere at temperatures up to about 900° C.
    一种制备高效率发射碱属激活的硫化镓荧光粉的方法,包括添加过量1-7%的。将可溶性盐的溶液加入碱硫酸盐的硫酸盐沉淀物中,在氢化气氛下在高达约900°C的温度下烧结。
  • Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections
    申请人:——
    公开号:US20020068761A1
    公开(公告)日:2002-06-06
    Methods are provided for the use of gallium complexes of 3-hydroxy-4-pyrones in the treatment or prevention of infections caused by a prokaryote of the genus Mycobacterium, including but not limited to those infections due to M. tuberculosis and M leprae . Methods are also provided for the treatment of immunocompromised patients infected by these and other mycobacteria species, including species (such as M. avium, M. aurum , and M. smegmatis ) that are not pathogenic to immunocompetent individuals but may cause disease in immunocompromised patients.
    本文提供了使用3-羟基-4-吡喃酮配合物治疗或预防由Mycobacterium属的原核生物引起的感染的方法,包括但不限于由结核分枝杆菌和麻风分枝杆菌引起的感染。本文还提供了治疗免疫受损患者感染这些和其他分枝杆菌种类(包括对免疫能力正常个体无病原性但可能导致免疫受损患者患病的种类,如M. avium,M. aurum和M. smegmatis)的方法。
  • Methods and compositions to inhibit keratinocyte proliferation
    申请人:——
    公开号:US05747482A1
    公开(公告)日:1998-05-05
    Disclosed are methods to inhibit mammalian skin cell proliferation and, in particular, human keratinocyte proliferation by the topical administration of neutral gallium complexes.
    本发明涉及使用中性配合物通过局部给药来抑制哺乳动物皮肤细胞增殖,特别是人角质细胞增殖的方法。
  • Catalyst composition for selective catalytic reduction of exhaust gases
    申请人:Schermanz Karl
    公开号:US08975206B2
    公开(公告)日:2015-03-10
    A catalyst composition comprising a vanadate represented by the formula XVO4/S, wherein XVO4 stands for a Bi-, Sb-, Ga- and/or Al-vanadate optionally in mixture with one or more rare earth metal-vanadates, or in mixture with one or more transition metal-vanadates, or in mixture with one or more transition metal-vanadates and one or more rare earth metal-vanadates, and S is a support comprising TiO2, optionally in combination with a dopant and a process for the preparation of such catalyst compositions.
    一种催化剂组成物,包括由公式XVO4/S表示的酸盐,其中XVO4代表Bi-、Sb-、Ga-和/或Al-酸盐,可选地与一种或多种稀土酸盐混合使用,或与一种或多种过渡酸盐混合使用,或与一种或多种过渡酸盐和一种或多种稀土酸盐混合使用,而S是一种支撑材料,包括TiO2,可选地与掺杂剂组合使用,以及一种制备这种催化剂组成物的方法。
  • Alder; Schmitz-Josten, Justus Liebigs Annalen der Chemie, 1955, vol. 595, p. 1,25
    作者:Alder、Schmitz-Josten
    DOI:——
    日期:——
查看更多